Immix Biopharma 1 article

Immix Biopharma is a cell-therapy biotechnology company whose scientific identity centers on cell therapy oncology, with BCMA-targeted CAR-T therapy defining how the therapeutic cells are selected or engineered. Its cell-therapy architecture extends from AL amyloidosis cellular therapy to plasma cell targeting, with BCMA-directed cellular immunotherapy shaping potency, persistence, targeting or immune compatibility. GenoMethods keeps the cell-therapy modality and individual cellular products separate; the platform identity of Immix Biopharma also includes autologous T-cell engineering.